{"analyses":[{"ciLowerLimit":"31.27","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"48.36","estimateComment":"95% CI for difference in rates were constructed using Anderson-Hauck method.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Difference in MRD Negative Rates","paramValue":"39.81","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.36","upperLimit":"22.83","value":"17.1"},{"groupId":"OG001","lowerLimit":"50.05","upperLimit":"63.64","value":"56.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"216"},{"groupId":"OG001","value":"216"}],"units":"Participants"}],"description":"MRD negativity was defined as having \\< 1 CLL cell per 10,000 leucocytes in bone marrow.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants will receive obinutuzumab for 6 cycles and chlorambucil for 12 cycles. Cycles will comprise 28 days.","id":"OG000","title":"Obinutuzumab + Chlorambucil"},{"description":"Participants will receive obinutuzumab for 6 cycles and venetoclax for 12 cycles. Cycles will comprise 28 days.","id":"OG001","title":"Obinutuzumab + Venetoclax"}],"paramType":"NUMBER","populationDescription":"ITT population was defined as all randomized participants.","reportingStatus":"POSTED","timeFrame":"At the completion of treatment assessment 3 months after treatment completion (at approximately 15 months)","title":"Percentage of Participants With MRD Negativity in Bone Marrow as Measured by ASO-PCR at Completion of Treatment","type":"SECONDARY","unitOfMeasure":"percentage of participants"}